| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 603259.CN | WuXi AppTec Co., Ltd. Class A | 80.0 | ¤44,193 | CN |
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 67.0 | ¤13,804 | CN |
| 002653.CN | Haisco Pharmaceutical Group Co. Ltd. Cla | 69.1 | ¤8,397 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 91.3 | ¤5,980 | CN |
| 688336.CN | Sunshine Guojian Pharmaceutical (Shangha | 86.0 | ¤5,647 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300515.CN | Hunan Sundy Science and Technology Co., | 72.7 | ¤487 | CN |
| 301580.CN | Aidite (Qinhuangdao) Technology Co., Ltd | 62.3 | ¤537 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 62.5 | ¤547 | CN |
| 688046.CN | GemPharmatech Co., Ltd. Class A | 63.7 | ¤613 | CN |
| 300871.CN | Hvsen Biotechnology Co. Ltd. Class A | 67.1 | ¤634 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 67.0 | 21 | CN |
| 000423.CN | Dong-E-E-Jiao Co., Ltd. Class A | 70.7 | 20 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 73.1 | 10 | CN |
| 600867.CN | Tonghua Dongbao Pharmaceutical Co., Ltd. | 64.0 | 10 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 62.5 | 8 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 68.1 | 8 | CN |
| 002603.CN | Shijiazhuang Yiling Pharmaceutical Co., | 61.6 | 6 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 91.3 | 6 | CN |
| 002437.CN | Harbin Gloria Pharmaceuticals Co., Ltd. | 61.4 | 5 | CN |
| 300206.CN | Edan Instruments, Inc. Class A | 65.9 | 5 | CN |
| Average Market Cap | ¤4,244 |
| Median Market Cap | ¤1,871 |
| Avg. 3 Mo. Dollar Vol. | ¤53,519,163 |
| Avg. 3 Mo. Trading Vol. | 8,146,264 |
| Last Rebalance Date | 12/22/2025 |
| Companies Replaced | 16 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 18.3 |
| Forward P/E Ratio (12 Mo.) | 15.1 |
| Price/Book Ratio | 3.4 |
| Avg. Revenue Chg. - 3 Yr | 59.9% |
| Avg. Op. Income Chg. - 3 Yr. | 102.5% |
| Avg. EPS Growth - 3 Yr. | 27.4% |
| Avg. EPS Growth - 1 Yr. | 16.6% |
| Avg. Operating Margin | 25.6% |
| Avg. LT Debt to Total Capital | 4.9% |
| Avg. Return on Equity | 15.8% |
| Dividend Yield | 1.8% |
| China Health Care Index | 65.93 |
| China | 100.0% |
